Cofrogliptin vs Teneligliptin

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline

Cofrogliptin

Marketed by Haisco Pharmaceutical Group

Phase 3 in Type 2 Diabetessmall molecule
Reliable signal

NCT04556851 · Phase 3 · completed

This randomized, double-blind, placebo-controlled trial enrolled 476 patients and measured change in HbA1c, a standard efficacy measure in diabetes, at 24 weeks. Both HSK7653 doses lowered HbA1c significantly more than placebo (p<0.0001), meeting the trial's primary goal.

Next expected readout: June 2027 · NCT07122102 (registry estimate)

Reported efficacy

HbA1c Change From Baseline at Week 24 (Baseline and week 24): HbA1c change from baseline to week 24 (LS mean, SE): cofrogliptin (HSK7653) 10 mg -0.96% (0.063), 25 mg -0.99% (0.064), linagliptin 5 mg -1.07% (0.065); non-inferiority margin of 0.4% met for both cofrogliptin doses vs linagliptin (met)

Result source: NCT04564872

Teneligliptin · Tenelia

Marketed by Tanabe Pharma Corporation and partners

Phase 3 in Type 2 Diabetessmall molecule
Partial signal

NCT00974090 · Phase 3 · completed

This randomized, double-blind, placebo-controlled Phase 3 trial added teneligliptin 20 mg or placebo to glimepiride in 194 Japanese adults with type 2 diabetes. The primary endpoint was the change in HbA1c at week 12. Teneligliptin lowered HbA1c by 1.0 percentage point more than placebo (p<0.001), so the primary endpoint was met. A 40-week open-label teneligliptin period followed. Source: the peer-reviewed trial report (Kadowaki and Kondo 2014) and CT.gov posted results.

Reported efficacy

HbA1c (Change from Visit 1(Baseline Visit) in HbA1c at Visit 5(week 16)): Change in HbA1c from baseline to week 16, teneligliptin (MP-513) vs placebo (both plus metformin): between-group difference -0.78 percentage points; fasting plasma glucose difference -1.24 mmol/L (22.42 mg/dL). (met)

Result source: NCT01805830

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCofrogliptinTeneligliptin
HbA1c, change-1.0% vs -1.1%avs linagliptin 5 mgcofrogliptin (HSK7653) 25 mg · wk 24NCT04564872
1 other result
  • -1.0% vs -1.1% cofrogliptin (HSK7653) 10 mg · wk 24 · Phase 3 · primary NCT04564872
-0.7% vs -0.0%−0.7 vs placebo20 mg · wk 24 · n 122NCT02924064
12 other results
  • -0.9% vs -0.1% 20 mg · wk 24 · n 125 · Phase 3 · primary NCT02916706
  • -0.6% vs 0.2% 20 mg · wk 12 · n 99 · Phase 3 · primary NCT00998881
  • -0.9% vs 0% wk 24 · n 77 · Phase 3 · primary NCT02354222
  • -0.7% vs 0.3% wk 12 · n 96 · Phase 3 · primary NCT00974090
  • -0.8% vs 0.1% 20 mg · wk 12 · n 79 · Phase 2 · primary NCT00628212
  • -0.8% vs 0.1% 10 mg · wk 12 · n 84 · Phase 2 · primary NCT00628212
  • -0.9% vs -0.3% 40 mg · wk 24 · n 88 · Phase 2 · primary NCT00971243
  • -0.9% vs 0.1% 40 mg · wk 12 · n 81 · Phase 2 · primary NCT00628212
  • -0.8% vs -0.3% 20 mg · wk 24 · n 91 · Phase 2 · primary NCT00971243
  • -0.7% vs -0.3% 10 mg · wk 24 · n 93 · Phase 2 · primary NCT00971243
  • -0.6% vs -0.3% 5 mg · wk 24 · n 87 · Phase 2 · primary NCT00971243
  • -0.9% vs -0.1% wk 16 · n 77 · Phase 4 · primary NCT02081599
Body weight, change (kg)—Not posted · NCT04564872—Not posted · NCT01798238
HbA1c below 7%—Not posted · NCT04564872—Not posted · NCT01798238
Fasting plasma glucose, change—Not posted · NCT04564872-0.8 vs 0.2−0.9 vs placebo20 mg · wk 24 · n 122NCT02924064
13 other results
  • -1.2 vs -0.1 20 mg · wk 24 · n 125 · Phase 3 · secondary NCT02916706
  • -1.1 vs -0.0 20 mg · wk 12 · n 99 · Phase 3 · secondary NCT00998881
  • -1.1 vs -0.4 20 mg · wk 4 · n 33 · Phase 3 · secondary NCT01072331
  • -1.1 vs -0.4 10 mg · wk 4 · n 34 · Phase 3 · secondary NCT01072331
  • -0.3 vs 0.6 wk 24 · n 77 · Phase 3 · secondary NCT02354222
  • -0.8 vs 0.2 20 mg · wk 12 · n 79 · Phase 2 · secondary NCT00628212
  • -0.8 vs 0.2 10 mg · wk 12 · n 84 · Phase 2 · secondary NCT00628212
  • -1.2 vs -0.2 40 mg · wk 24 · n 88 · Phase 2 · secondary NCT00971243
  • -0.9 vs 0.2 40 mg · wk 12 · n 81 · Phase 2 · secondary NCT00628212
  • -1.0 vs -0.2 20 mg · wk 24 · n 91 · Phase 2 · secondary NCT00971243
  • -0.8 vs -0.2 10 mg · wk 24 · n 93 · Phase 2 · secondary NCT00971243
  • -0.9 vs -0.2 5 mg · wk 24 · n 87 · Phase 2 · secondary NCT00971243
  • -0.3 vs 0.4 wk 16 · n 77 · Phase 4 · secondary NCT02081599
3-point MACE (% with event)—Not posted · NCT04564872—Not posted · NCT01798238

HbA1c, change

Cofrogliptin
-1.0% vs -1.1%avs linagliptin 5 mgcofrogliptin (HSK7653) 25 mg · wk 24NCT04564872
1 other result
  • -1.0% vs -1.1% cofrogliptin (HSK7653) 10 mg · wk 24 · Phase 3 · primary NCT04564872
Teneligliptin
-0.7% vs -0.0%−0.7 vs placebo20 mg · wk 24 · n 122NCT02924064
12 other results
  • -0.9% vs -0.1% 20 mg · wk 24 · n 125 · Phase 3 · primary NCT02916706
  • -0.6% vs 0.2% 20 mg · wk 12 · n 99 · Phase 3 · primary NCT00998881
  • -0.9% vs 0% wk 24 · n 77 · Phase 3 · primary NCT02354222
  • -0.7% vs 0.3% wk 12 · n 96 · Phase 3 · primary NCT00974090
  • -0.8% vs 0.1% 20 mg · wk 12 · n 79 · Phase 2 · primary NCT00628212
  • -0.8% vs 0.1% 10 mg · wk 12 · n 84 · Phase 2 · primary NCT00628212
  • -0.9% vs -0.3% 40 mg · wk 24 · n 88 · Phase 2 · primary NCT00971243
  • -0.9% vs 0.1% 40 mg · wk 12 · n 81 · Phase 2 · primary NCT00628212
  • -0.8% vs -0.3% 20 mg · wk 24 · n 91 · Phase 2 · primary NCT00971243
  • -0.7% vs -0.3% 10 mg · wk 24 · n 93 · Phase 2 · primary NCT00971243
  • -0.6% vs -0.3% 5 mg · wk 24 · n 87 · Phase 2 · primary NCT00971243
  • -0.9% vs -0.1% wk 16 · n 77 · Phase 4 · primary NCT02081599

Body weight, change (kg)

Cofrogliptin
—Not posted · NCT04564872
Teneligliptin
—Not posted · NCT01798238

HbA1c below 7%

Cofrogliptin
—Not posted · NCT04564872
Teneligliptin
—Not posted · NCT01798238

Fasting plasma glucose, change

Cofrogliptin
—Not posted · NCT04564872
Teneligliptin
-0.8 vs 0.2−0.9 vs placebo20 mg · wk 24 · n 122NCT02924064
13 other results
  • -1.2 vs -0.1 20 mg · wk 24 · n 125 · Phase 3 · secondary NCT02916706
  • -1.1 vs -0.0 20 mg · wk 12 · n 99 · Phase 3 · secondary NCT00998881
  • -1.1 vs -0.4 20 mg · wk 4 · n 33 · Phase 3 · secondary NCT01072331
  • -1.1 vs -0.4 10 mg · wk 4 · n 34 · Phase 3 · secondary NCT01072331
  • -0.3 vs 0.6 wk 24 · n 77 · Phase 3 · secondary NCT02354222
  • -0.8 vs 0.2 20 mg · wk 12 · n 79 · Phase 2 · secondary NCT00628212
  • -0.8 vs 0.2 10 mg · wk 12 · n 84 · Phase 2 · secondary NCT00628212
  • -1.2 vs -0.2 40 mg · wk 24 · n 88 · Phase 2 · secondary NCT00971243
  • -0.9 vs 0.2 40 mg · wk 12 · n 81 · Phase 2 · secondary NCT00628212
  • -1.0 vs -0.2 20 mg · wk 24 · n 91 · Phase 2 · secondary NCT00971243
  • -0.8 vs -0.2 10 mg · wk 24 · n 93 · Phase 2 · secondary NCT00971243
  • -0.9 vs -0.2 5 mg · wk 24 · n 87 · Phase 2 · secondary NCT00971243
  • -0.3 vs 0.4 wk 16 · n 77 · Phase 4 · secondary NCT02081599

3-point MACE (% with event)

Cofrogliptin
—Not posted · NCT04564872
Teneligliptin
—Not posted · NCT01798238
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. Cofrogliptin: 1 of 5 rows · Teneligliptin: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCofrogliptin
Rows use multiple source trials
Teneligliptin
Rows use multiple source trials
HbA1c
absolute change · percentage points
No placebo or comparator arm
-0.59% @ 24wk25 mga,b,c
NCT04556851 · Phase 3 · sponsor-reported, not registry data
show 1 more dose
-0.63% @ 24wkcofrogliptin (HSK7653) 10 mg
NCT04556851 · Phase 3 · sponsor-reported, not registry data
-0.94% @ 24wkteneligliptin 20mgb,c
NCT01798238 · Phase 3 · sponsor-reported, not registry data
Dropout rate—
1%Teneli / Teneli + SUd
NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 28 more results
—Teneli/Teneli + SU (Data Through W
NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3
—Teneli/Teneli + SU (Data Through W
NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3
10.6%Teneligliptin
NCT02314637 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
15.7%Teneligliptin + Sulfonylurea
NCT02314637 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.6%Teneli (Teneligliptin) /Teneli + I
NCT02081599 · Phase 4 · registry result, not featured evidence · combination
—Teneli (Teneligliptin) /Teneli + I
NCT02081599 · Phase 4 · registry result, not featured evidence · combination
—Teneli (Teneligliptin)/Teneli + In
NCT02081599 · Phase 4 · registry result, not featured evidence · combination
19.5%20 mg
NCT02924064 · Phase 3 · registry result, not featured evidence · combination
11.8%20 mg
NCT02916706 · Phase 3 · registry result, not featured evidence
7.2%
NCT02220907 · Phase 3 · registry result, not featured evidence · combination
5.2%
NCT02354222 · Phase 3 · registry result, not featured evidence · combination
7.1%Teneligliptin
NCT01301833 · Phase 3 · registry result, not featured evidence
9.3%Teneligliptin and Alpha-glucosidas
NCT01301833 · Phase 3 · registry result, not featured evidence · combination
7.4%Teneligliptin and Biguanide
NCT01301833 · Phase 3 · registry result, not featured evidence · combination
10%Teneligliptin and Glinide
NCT01301833 · Phase 3 · registry result, not featured evidence · combination
0%20 mg
NCT01072331 · Phase 3 · registry result, not featured evidence
0%10 mg
NCT01072331 · Phase 3 · registry result, not featured evidence
2%20 mg
NCT00998881 · Phase 3 · registry result, not featured evidence
—40 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
15.9%40 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
—20 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
20.9%20 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
—10 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
11.8%10 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
21.8%5 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
3.8%20 mg
NCT00628212 · Phase 2 · registry result, not featured evidence
1.2%10 mg
NCT00628212 · Phase 2 · registry result, not featured evidence
6.2%40 mg
NCT00628212 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs—
1%Teneli / Teneli + SUd
NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 28 more results
—Teneli/Teneli + SU (Data Through W
NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3
—Teneli/Teneli + SU (Data Through W
NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.6%Teneligliptin
NCT02314637 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
9%Teneligliptin + Sulfonylurea
NCT02314637 · Phase 3 · combination · Type 2 Diabetes · phase 3
0%Teneli (Teneligliptin) /Teneli + I
NCT02081599 · Phase 4 · registry result, not featured evidence · combination
—Teneli (Teneligliptin) /Teneli + I
NCT02081599 · Phase 4 · registry result, not featured evidence · combination
—Teneli (Teneligliptin)/Teneli + In
NCT02081599 · Phase 4 · registry result, not featured evidence · combination
1.6%20 mg
NCT02924064 · Phase 3 · registry result, not featured evidence · combination
0%20 mg
NCT02916706 · Phase 3 · registry result, not featured evidence
4.6%
NCT02220907 · Phase 3 · registry result, not featured evidence · combination
0%
NCT02354222 · Phase 3 · registry result, not featured evidence · combination
3.3%Teneligliptin
NCT01301833 · Phase 3 · registry result, not featured evidence
6.7%Teneligliptin and Alpha-glucosidas
NCT01301833 · Phase 3 · registry result, not featured evidence · combination
5.3%Teneligliptin and Biguanide
NCT01301833 · Phase 3 · registry result, not featured evidence · combination
6.3%Teneligliptin and Glinide
NCT01301833 · Phase 3 · registry result, not featured evidence · combination
—20 mg
NCT01072331 · Phase 3 · registry result, not featured evidence
—10 mg
NCT01072331 · Phase 3 · registry result, not featured evidence
2%20 mg
NCT00998881 · Phase 3 · registry result, not featured evidence
—40 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
2.3%40 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
—20 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
2.2%20 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
—10 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
3.2%10 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
2.3%5 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
1.3%20 mg
NCT00628212 · Phase 2 · registry result, not featured evidence
0%10 mg
NCT00628212 · Phase 2 · registry result, not featured evidence
2.5%40 mg
NCT00628212 · Phase 2 · registry result, not featured evidence
Serious AEs—
—Teneli / Teneli + SUd
NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 28 more results
0%Teneli/Teneli + SU (Data Through W
NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3
7.3%Teneli/Teneli + SU (Data Through W
NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3
4%Teneligliptin
NCT02314637 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
7.9%Teneligliptin + Sulfonylurea
NCT02314637 · Phase 3 · combination · Type 2 Diabetes · phase 3
—Teneli (Teneligliptin) /Teneli + I
NCT02081599 · Phase 4 · registry result, not featured evidence · combination
6.5%Teneli (Teneligliptin) /Teneli + I
NCT02081599 · Phase 4 · registry result, not featured evidence · combination
1.3%Teneli (Teneligliptin)/Teneli + In
NCT02081599 · Phase 4 · registry result, not featured evidence · combination
3.2%20 mg
NCT02924064 · Phase 3 · registry result, not featured evidence · combination
4.7%20 mg
NCT02916706 · Phase 3 · registry result, not featured evidence
7.2%
NCT02220907 · Phase 3 · registry result, not featured evidence · combination
1.3%
NCT02354222 · Phase 3 · registry result, not featured evidence · combination
6.6%Teneligliptin
NCT01301833 · Phase 3 · registry result, not featured evidence
8%Teneligliptin and Alpha-glucosidas
NCT01301833 · Phase 3 · registry result, not featured evidence · combination
6.3%Teneligliptin and Biguanide
NCT01301833 · Phase 3 · registry result, not featured evidence · combination
3.8%Teneligliptin and Glinide
NCT01301833 · Phase 3 · registry result, not featured evidence · combination
0%20 mg
NCT01072331 · Phase 3 · registry result, not featured evidence
0%10 mg
NCT01072331 · Phase 3 · registry result, not featured evidence
0%20 mg
NCT00998881 · Phase 3 · registry result, not featured evidence
5.7%40 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
—40 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
3.3%20 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
—20 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
4.3%10 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
—10 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
4.6%5 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
0%20 mg
NCT00628212 · Phase 2 · registry result, not featured evidence
0%10 mg
NCT00628212 · Phase 2 · registry result, not featured evidence
0%40 mg
NCT00628212 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs—
d
nasopharyngitis 19.8% (placebo 27.4%)
upper respiratory tract inflammation 5.2% (placebo 7.4%)
alanine aminotransferase increased 4.2% (placebo 3.2%)
NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 23 more results
nasopharyngitis 33.3% (placebo 27.4%)
protein urine present 16.7% (placebo 13.7%)
glucose urine present 11.5% (placebo 17.9%)
NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3
nasopharyngitis 37.1%
blood creatine phosphokinase increased 9.3%
protein urine present 9.3%
NCT02314637 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
nasopharyngitis 32.6%
glucose urine present 18%
protein urine present 14.6%
NCT02314637 · Phase 3 · combination · Type 2 Diabetes · phase 3
nasopharyngitis 28.6% (placebo 18.3%)
hypoglycaemia 27.3% (placebo 7%)
constipation 10.4% (placebo 2.8%)
NCT02081599 · Phase 4 · registry result, not featured evidence · combination
hypoglycaemia 11.7% (placebo 7%)
nasopharyngitis 7.8% (placebo 18.3%)
constipation 3.9% (placebo 2.8%)
NCT02081599 · Phase 4 · registry result, not featured evidence · combination
20 mg
upper respiratory tract infection 11.3% (placebo 17.9%)
hyperuricaemia 8.9% (placebo 10.6%)
hyperlipidaemia 6.5% (placebo 5.7%)
NCT02924064 · Phase 3 · registry result, not featured evidence · combination
20 mg
upper respiratory tract infection 23.6% (placebo 15.7%)
hyperuricaemia 8.7% (placebo 4.7%)
proteinuria 7.1% (placebo 3.9%)
NCT02916706 · Phase 3 · registry result, not featured evidence
nasopharyngitis 30.7%
pollakiuria 6.5%
constipation 5.2%
NCT02220907 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 15.6% (placebo 10.4%)
upper respiratory tract infection 5.2% (placebo 0%)
NCT02354222 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 29.2%
upper respiratory tract inflammation 9.4%
blood urine present 7.1%
NCT01301833 · Phase 3 · registry result, not featured evidence
nasopharyngitis 28%
upper respiratory tract inflammation 10.7%
eczema 9.3%
NCT01301833 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 29.5%
upper respiratory tract inflammation 10.5%
blood urine present 9.5%
NCT01301833 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 23.8%
upper respiratory tract inflammation 13.8%
bronchitis 8.8%
NCT01301833 · Phase 3 · registry result, not featured evidence · combination
20 mg
nasopharyngitis 6.1% (placebo 0%)
blood triglycerides increased 3% (placebo 3.1%)
diarrhoea 3% (placebo 0%)
NCT01072331 · Phase 3 · registry result, not featured evidence
10 mg
upper respiratory tract inflammation 8.8% (placebo 0%)
nasopharyngitis 5.9% (placebo 0%)
alanine aminotransferase increased 2.9% (placebo 0%)
NCT01072331 · Phase 3 · registry result, not featured evidence
20 mg
nasopharyngitis 12.1% (placebo 6.7%)
glucose urine present 4% (placebo 6.7%)
upper respiratory tract inflammation 4% (placebo 3.8%)
NCT00998881 · Phase 3 · registry result, not featured evidence
40 mg
nasopharyngitis 8% (placebo 6.8%)
cystitis 5.7% (placebo 1.1%)
gastroenteritis 3.4% (placebo 2.3%)
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
20 mg
diarrhoea 5.5% (placebo 3.4%)
headache 5.5% (placebo 1.1%)
hypertension 3.3% (placebo 2.3%)
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
10 mg
cystitis 4.3% (placebo 1.1%)
nasopharyngitis 4.3% (placebo 6.8%)
bronchitis 3.2% (placebo 1.1%)
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
5 mg
nasopharyngitis 6.9% (placebo 6.8%)
hypertension 5.7% (placebo 2.3%)
bronchitis 3.4% (placebo 1.1%)
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
20 mg
nasopharyngitis 11.4% (placebo 13.8%)
glucose urine present 5.1% (placebo 7.5%)
urine ketone body present 5.1% (placebo 1.3%)
NCT00628212 · Phase 2 · registry result, not featured evidence
10 mg
nasopharyngitis 19% (placebo 13.8%)
blood creatine phosphokinase increased 4.8% (placebo 1.3%)
blood urine present 4.8% (placebo 1.3%)
NCT00628212 · Phase 2 · registry result, not featured evidence
40 mg
nasopharyngitis 17.3% (placebo 13.8%)
arthropod sting 3.7% (placebo 0%)
glucose urine present 3.7% (placebo 7.5%)
NCT00628212 · Phase 2 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dPopulation comparability has not been reviewed for 24 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Teneligliptin

FPG -0.96 vs 0.54 placebo mmol/L @ 12wk
absolute change · mmol/L
NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -17.3 mg/dL as posted
AUC0-2h PPG -73.124 vs 0.224 placebo mg @ 12wk20 mg
absolute change · mg
NCT00998881 · Phase 3 · registry result, not featured evidence
show 5 more results
-73.211 vs 5.897 placebo mg @ 12wk20 mg
NCT00628212 · Phase 2 · registry result, not featured evidence
-65.445 vs 5.897 placebo mg @ 12wk10 mg
NCT00628212 · Phase 2 · registry result, not featured evidence
-75.326 vs 5.897 placebo mg @ 12wk40 mg
NCT00628212 · Phase 2 · registry result, not featured evidence
-65.544 vs 15.514 placebo mg @ 12wk
NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3
-54.035 vs 9.827 placebo mg @ 16wk
NCT02081599 · Phase 4 · registry result, not featured evidence · combination
PPG 2 h -2.39 vs 0.33 placebo mmol/L @ 12wk
absolute change · mmol/L
NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -43.1 mg/dL as posted
Fasting Plasma Glucose -1.21 mmol/Lteneligliptin 20mg
absolute change · mmol/L
No placebo or comparator arm
NCT01798238 · Phase 3 · sponsor-reported, not registry data
show 7 more results
-0.69 mmol/L @ 52wk*
NCT02314637 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to mmol/L from -12.4 mg/dL as posted
-0.94 mmol/L @ 52wk*
NCT02314637 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -17 mg/dL as posted
-2.14 mmol/L @ 52wk*
NCT02220907 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -38.6 mg/dL as posted
-0.65 mmol/L @ 52wk*
NCT01301833 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -11.7 mg/dL as posted
-0.76 mmol/L @ 52wk*
NCT01301833 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -13.7 mg/dL as posted
-0.7 mmol/L @ 52wk*
NCT01301833 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -12.7 mg/dL as posted
-1.08 mmol/L @ 52wk*
NCT01301833 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -19.5 mg/dL as posted
Fasting Plasma Glucose -0.75 vs 0.17 placebo mmol/L @ 24wk20 mg
absolute change · mmol/L
NCT02924064 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -13.5 mg/dL as posted
show 13 more results
-1.22 vs -0.08 placebo mmol/L @ 24wk*20 mg
NCT02916706 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -21.9 mg/dL as posted
-1.14 vs -0.38 placebo mmol/L @ 4wk*20 mg
NCT01072331 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -20.5 mg/dL as posted
-1.07 vs -0.01 placebo mmol/L @ 12wk*20 mg
NCT00998881 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -19.2 mg/dL as posted
-0.78 vs 0.16 placebo mmol/L @ 12wk*20 mg
NCT00628212 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -14.1 mg/dL as posted
-1.15 vs -0.38 placebo mmol/L @ 4wk*10 mg
NCT01072331 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -20.7 mg/dL as posted
-0.83 vs 0.16 placebo mmol/L @ 12wk*10 mg
NCT00628212 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -15 mg/dL as posted
-1.21 vs -0.19 placebo mmol/L @ 24wk*40 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination · converted to mmol/L from -21.85 mg/dL as posted
-0.95 vs 0.16 placebo mmol/L @ 12wk*40 mg
NCT00628212 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -17.2 mg/dL as posted
-0.99 vs -0.19 placebo mmol/L @ 24wk*20 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination · converted to mmol/L from -17.84 mg/dL as posted
-0.76 vs -0.19 placebo mmol/L @ 24wk*10 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination · converted to mmol/L from -13.65 mg/dL as posted
-0.86 vs -0.19 placebo mmol/L @ 24wk*5 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination · converted to mmol/L from -15.54 mg/dL as posted
-0.3 vs 0.44 placebo mmol/L @ 16wk*
NCT02081599 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from -5.4 mg/dL as posted
-0.31 vs 0.56 placebo mmol/L @ 24wk*
NCT02354222 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -5.6 mg/dL as posted
PPG 2h Change mg/dL -2.66 vs -0.18 placebo mmol/L @ 12wk20 mg
absolute change · mmol/L
NCT00998881 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -47.9 mg/dL as posted
show 5 more results
-2.74 vs 0.41 placebo mmol/L @ 12wk*20 mg
NCT00628212 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -49.4 mg/dL as posted
-2.4 vs 0.41 placebo mmol/L @ 12wk*10 mg
NCT00628212 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -43.3 mg/dL as posted
-2.85 vs 0.41 placebo mmol/L @ 12wk*40 mg
NCT00628212 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -51.3 mg/dL as posted
-2.38 vs 0.17 placebo mmol/L @ 16wk*
NCT02081599 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from -42.9 mg/dL as posted
-1.96 vs 0.13 placebo mmol/L @ 24wk*
NCT02354222 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -35.3 mg/dL as posted
Weight -3.92% (n=152) @ 52wk
percent change · % of baseline
No placebo or comparator arm
NCT02220907 · Phase 3 · registry result, not featured evidence · combination
Weight 0.09% (n=77) vs -1.34% (n=76) placebo @ 24wk
percent change · % of baseline
NCT02354222 · Phase 3 · registry result, not featured evidence · combination
AUC0-2h PPG -2.79 vs 0.32 placebo mmol/L @ 24wk
absolute change · mmol/L
NCT02354222 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -50.2 mg/dL as posted
Glucose Change mg/dL -1.72 vs -0.3 placebo mmol/L @ 4wk20 mg
absolute change · mmol/L
NCT01072331 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -30.921 mg/dL as posted
show 1 more result
-1.93 vs -0.3 placebo mmol/L @ 4wk*10 mg
NCT01072331 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -34.722 mg/dL as posted

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cofrogliptin's landscape · Teneligliptin's landscape